The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

The updated NCCN Guidelines now include HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant uveal melanoma. Previously, the guidelines limited its use to patients with ...